Format

Send to:

Choose Destination
See comment in PubMed Commons below
Heart Fail Clin. 2014 Jul;10(3):471-9. doi: 10.1016/j.hfc.2014.04.005.

Novel biomarkers in heart failure with preserved ejection fraction.

Author information

  • 1Department of Internal Medicine, University of California, San Diego, 402 Dickinson Street, Suite 380, San Diego, CA 92103-8425, USA.
  • 2Cardiology Section (9111-A), VA San Diego Healthcare System, 3350 La Jolla Village Drive, San Diego, CA 92161, USA. Electronic address: amaisel@ucsd.edu.

Abstract

Heart failure with preserved ejection fraction (HFPEF) is a common subtype of heart failure with morbidity and mortality similar to that of heart failure with systolic dysfunction. This article discusses the numerous biomarkers that promise to play a substantial role in terms of our ability to understand the mechanisms of HFPEF and discern possible phenotypes that respond to targeted therapies: natriuretic peptides, high-sensitivity troponins, galectin-3, soluble ST2, neutrophil gelatinase-associated lipocalin, and cystatin C.

Published by Elsevier Inc.

KEYWORDS:

Biomarkers; Diagnosis; Heart failure; Preserved ejection fraction; Prognosis

PMID:
24975910
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk